Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter H Gann

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
JAMA Internal Medicine|October 8, 2019
Benefits of Targeted Use of 5α-Reductase Inhibitors in Patients With Prostate CancerPeter H Gann
JAMA|December 11, 2008
Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance--next, causePeter H Gann
Reviews in Urology|September 21, 2006
Risk factors for prostate cancerPeter H Gann
Urology|February 1, 2003
Informed consent for prostate-specific antigen testingPeter H Gann
The Journal of Nutrition|July 28, 2005
Intermediate biomarkers of lycopene/tomato effects in high-risk prostatic tissuePeter H Gann
Nature Reviews. Urology|October 9, 2010
Prostate cancer: A closer look at the initial results from the REDUCE trialPeter H Gann
JAMA|May 5, 2005
The natural history of clinically localized prostate cancerPeter H Gann, Misop Han
JAMA|June 26, 2003
Combined hormone therapy and breast cancer: a single-edged swordPeter H Gann, Monica Morrow
Journal of the National Cancer Institute|November 6, 2003
Tomatoes or lycopene versus prostate cancer: is evolution anti-reductionist?Peter H Gann, Frederick Khachik
Nature Clinical Practice. Urology|July 5, 2007
Does active treatment improve survival in elderly men with localized prostate cancer?Margaret E Wright, Peter H Gann
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
JAMA Internal Medicine|October 8, 2019
Benefits of Targeted Use of 5α-Reductase Inhibitors in Patients With Prostate CancerPeter H Gann
JAMA|December 11, 2008
Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance--next, causePeter H Gann
Reviews in Urology|September 21, 2006
Risk factors for prostate cancerPeter H Gann
Urology|February 1, 2003
Informed consent for prostate-specific antigen testingPeter H Gann
The Journal of Nutrition|July 28, 2005
Intermediate biomarkers of lycopene/tomato effects in high-risk prostatic tissuePeter H Gann
Nature Reviews. Urology|October 9, 2010
Prostate cancer: A closer look at the initial results from the REDUCE trialPeter H Gann
JAMA|May 5, 2005
The natural history of clinically localized prostate cancerPeter H Gann, Misop Han
JAMA|June 26, 2003
Combined hormone therapy and breast cancer: a single-edged swordPeter H Gann, Monica Morrow
Journal of the National Cancer Institute|November 6, 2003
Tomatoes or lycopene versus prostate cancer: is evolution anti-reductionist?Peter H Gann, Frederick Khachik
Nature Clinical Practice. Urology|July 5, 2007
Does active treatment improve survival in elderly men with localized prostate cancer?Margaret E Wright, Peter H Gann
Pageof 11